Skip to main content
S. 3311 118th Congress Senate

American Made Pharmaceuticals Act of 2023

Official title: A bill to direct the Secretary of Health and Human Services to conduct a demonstration program to test providing preferential treatment under the Medicare, Med… Show full official titleShow less

Official title: A bill to direct the Secretary of Health and Human Services to conduct a demonstration program to test providing preferential treatment under the Medicare, Medicaid, and CHIP programs for certain drugs and biologicals manufactured in the United States.

Introduced: December 6, 2023 Introduced by: Tina Smith Democratic · Minnesota See on congress.gov
Health Buy American requirementsChild healthCongressional oversightDrug therapy
More subjectsShow fewer subjects
Emergency medical services and trauma careHealth care costs and insuranceHealth technology, devices, suppliesInfectious and parasitic diseasesManufacturingMedicaidMedicarePoverty and welfare assistancePrescription drugsPublic contracts and procurement
Sign in to write a letter Sign in to watch
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 25, 2024
Committee on Banking, Housing, and Urban Affairs. Hearings held. Hearings printed: S.Hrg. 118-655.
Nov 15, 2023
Read twice and referred to the Committee on Finance.
Nov 15, 2023
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action July 25, 2024

Committee on Banking, Housing, and Urban Affairs. Hearings held. Hearings printed: S.Hrg. 118-655.

 Plain-English summary Congressional Research Service

American Made Pharmaceuticals Act of 2023

This bill requires the Centers for Medicare & Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).

The program must be conducted in at least eight states and for at least seven years. Applicable drugs include critical drugs that are needed to respond to a public health emergency and that have a vulnerable global supply chain. Preference may take the form of reduced cost-sharing, preferential treatment on formularies, bonus payments, and other specified methods.

 Related & companion bills 1
  • S 3991 Reintroduction of American Made Pharmaceuticals Act of 2022
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 2
All 2 Democratic 1 Republican 1
D
Bennet, Michael F.
Colorado · Dec 6, 2023
 R
Cotton, Tom
Arkansas · Nov 15, 2023
Cite this page click to expand
APA
U.S. Congress. (2026). S. 3311: American Made Pharmaceuticals Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-S-3311/
MLA
"S. 3311: American Made Pharmaceuticals Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-3311/.
Bluebook (legal)
S. 3311, 118th Cong. (2026), https://openamerica.io/bill/118-S-3311/.
Markdown link
[S. 3311: American Made Pharmaceuticals Act of 2023](https://openamerica.io/bill/118-S-3311/)
Report a problem